<DOC>
	<DOCNO>NCT01264302</DOCNO>
	<brief_summary>The objective study evaluate relative bioavailability test formulation finasteride 5 mg tablet ( Dr. Reddy 's Laboratories Limited ) reference formulation PROSCARÂ® 5 mg Tablet ( Merck &amp; Co. , Inc. ) feed condition healthy adult male subject .</brief_summary>
	<brief_title>Bioequivalence Study Two Finasteride 5 mg Tablet Formulations Under Non-Fasting Conditions</brief_title>
	<detailed_description>This randomize , single-dose , two-treatment , two-way , crossover study conduct compare relative bioavailability two formulation 5 mg finasteride tablet feed condition . The study conduct 26 ( 24 complete ) healthy adult . The subject receive test product one study period reference product period ; order administration accord dose randomization schedule . There 7-day interval treatment .</detailed_description>
	<mesh_term>Finasteride</mesh_term>
	<criteria>1 . Males , 1865 year age ( inclusive ) . 2 . A body mass index ( BMI ) 1830 kg/m2 inclusive calculate accord Novum Standard Operating Procedures . 3 . Good health determine lack clinically significant abnormality health assessment perform screen . 4 . Signed date informed consent form , meet criteria current FDA regulation . 1 . Female . 2 . History allergy sensitivity finasteride , similar drug , history drug hypersensitivity intolerance , opinion Investigator , would compromise safety subject study . 3 . Significant history current evidence chronic infectious disease , system disorder organ dysfunction . 4 . Presence gastrointestinal disease history malabsorption within last year . 5 . History psychiatric disorder occur within last two year require hospitalization medication . 6 . Presence medical condition require regular treatment prescription drug . 7 . Use pharmacologic agent know significantly induce inhibit drugmetabolizing enzyme within 30 day prior initial dosing . 8 . Receipt drug part research study within 30 day prior dose . 9 . Drug alcohol addiction require treatment past 12 month . 10 . Donation significant loss whole blood ( 480 ml ) within 30 day plasma within 14 day prior dose . 11 . Positive test result HIV , Hepatitis B surface antigen , Hepatitis C antibody . 12 . Positive test result drug abuse screening .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Finasteride</keyword>
	<keyword>crossover</keyword>
</DOC>